About Us

Endovascular Engineering, Inc. (“E2”), is a mission-driven, venture-backed company focused on the development and deployment of next generation clot removal technologies that target venous thromboembolism.

Leadership Team

Dan Rose
Dan Rose
Chief Executive Officer
Mike Rosenthal
Mike Rosenthal
Chief Operations Officer
Scott Baron
Scott Baron
Chief Technology Officer
Luis Savastano, MD, PhD
Luis Savastano, MD, PhD
Founder, Chief Scientific Officer
Jennifer Beedon
Jennifer Beedon
VP of Strategic Operations
Debra Cogan
Debra Cogan
VP of Clinical and Regulatory Affairs
Keri Ng
Keri Ng
VP of Quality
Dave Snow
Dave Snow
VP of Research and Development
Torsten Kimura
Torsten Kimura
VP of Manufacturing Operations

Key Clinical Partners

Eric Secemsky, MD, MSc
Eric Secemsky, MD, MSc
Interventional Cardiology
Jay Giri, MD, MPH
Jay Giri, MD, MPH
Interventional Cardiology
Andrew Klein, MD
Andrew Klein, MD
Interventional Cardiology
Julie Bulman, MD
Julie Bulman, MD
Interventional Radiology
Kush Desai, MD
Kush Desai, MD
Interventional Radiology

Key INVESTORS

Press Releases

20 Aug, 2024

Endovascular Engineering Appoints Dan Rose as Chief Executive Officer

06 May, 2024

Endovascular Engineering Presents Positive Results from ENGULF Feasibility Trial with its Hēlo™ PE Thrombectomy System for the Treatment of Pulmonary Embolism

20 Feb, 2024

First Patient Enrolled in ENGULF Pivotal Trial with its Hēlo™ PE Thrombectomy System for the Treatment of Pulmonary Embolism

11 Jan, 2024

Hēlo™ Thrombectomy System Receives IDE Approval to Start ENGULF Pivotal Trial for the Treatment of Pulmonary Embolism